Climb Bio Inc (CLYM)

$2.25 -0.15 (-6.25%)
Market Cap 152.47M
Revenue (ttm) 0.00
Net Income (ttm) -73.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 405,100
Avg Vol 518,828
Day's Range N/A - N/A
Shares Out 67.76M
Stochastic %K 30%
Beta -0.05
Analysts Strong Sell
Price Target $9.00

Company Profile

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclo...

Industry: Biotechnology
Sector: Healthcare
Phone: 866 857 2596
Address:
20 William Street, Suite 145, Wellesley Hills, United States
cheating_stock_investor
cheating_stock_investor Sep. 3 at 4:50 PM
$CLYM when this board gets more activity some will say how was I here at the bottom again
0 · Reply
Ralphbeach
Ralphbeach Aug. 27 at 7:41 PM
$IXHL so many other stocks to invest in. This Australia dog has too many fleas. Too many hurdles...all the phases. All the cash needed. The pumpers on all the different social media. Too much competition with companies that have a stronger balance sheet. Look at $ACHV $CUE $LCTX $CLYM
3 · Reply
cheating_stock_investor
cheating_stock_investor Aug. 25 at 2:28 PM
$CLYM cash plus value of assets 3+2 minimum =5 Steal here.
0 · Reply
StockScanners
StockScanners Aug. 23 at 7:08 PM
$CLYM reached 2.42
2 · Reply
BigWins3
BigWins3 Aug. 23 at 11:17 AM
$CLYM This is my Grandpa Palphie, he pays for a stocktwits monthly membership and pretends he has lots of money, rest assured grandma left him because he was caught wearing her under garmets and playing dress up. I hate to air out our family's dirty laundry but he was wearing it so I have no choice.
1 · Reply
SpectreStrat
SpectreStrat Aug. 23 at 9:24 AM
$CLYM The Calamos Dynamic Convertible and Income Fund is a leveraged closed-end convertible fund
0 · Reply
Ralphbeach
Ralphbeach Aug. 23 at 1:18 AM
BIGwins...$CLYM take your lunch money and buy some. With your gains enroll in charm school. Peace ✌️ out
1 · Reply
cheating_stock_investor
cheating_stock_investor Aug. 22 at 2:14 PM
$CLYM very quiet board yet slow accumulation increase in stock price. Tells you this is the place to be with no noise
0 · Reply
StockScanners
StockScanners Aug. 21 at 12:32 AM
$CLYM keep watch if this holds above 2.10
0 · Reply
Chumpchange53
Chumpchange53 Aug. 20 at 9:30 PM
$CLYM Wash ,rinse, repeat kind of day
0 · Reply
Latest News on CLYM
Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025

Sep 4, 2025, 7:00 AM EDT - 10 days ago

Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025

UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences

Aug 25, 2025, 2:41 PM EDT - 19 days ago

UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences

Climb Bio to Present at Upcoming September 2025 Investor Conferences

Aug 25, 2025, 7:00 AM EDT - 20 days ago

Climb Bio to Present at Upcoming September 2025 Investor Conferences

Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 12, 2025, 7:00 AM EDT - 4 weeks ago

Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 19, 2025, 4:34 PM EDT - 4 months ago

Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

May 14, 2025, 7:00 AM EDT - 4 months ago

Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

Apr 1, 2025, 7:00 AM EDT - 5 months ago

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 7:00 AM EDT - 6 months ago

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference

Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates

Mar 25, 2025, 4:05 PM EDT - 6 months ago

Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates

Climb Bio to Present at Upcoming Investor Conferences

Feb 25, 2025, 7:00 AM EST - 7 months ago

Climb Bio to Present at Upcoming Investor Conferences

Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer

Feb 24, 2025, 7:00 AM EST - 7 months ago

Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer

Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 7:00 AM EST - 7 months ago

Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy

Jan 9, 2025, 7:00 AM EST - 8 months ago

Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy

Climb Bio to be Added to the Nasdaq Biotechnology Index

Dec 19, 2024, 7:00 AM EST - 9 months ago

Climb Bio to be Added to the Nasdaq Biotechnology Index

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 12, 2024, 4:05 PM EST - 10 months ago

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Climb Bio Appoints Douglas E. Williams, Ph.D.

Nov 11, 2024, 7:00 AM EST - 10 months ago

Climb Bio Appoints Douglas E. Williams, Ph.D.

Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event

Oct 15, 2024, 7:00 AM EDT - 11 months ago

Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event

Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024

Oct 11, 2024, 12:30 PM EDT - 1 year ago

Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024

Climb Bio to Present at William Blair's Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19

Oct 4, 2024, 7:00 AM EDT - 1 year ago

Climb Bio to Present at William Blair's Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19

Climb Bio to Host Virtual Investor Event on October 15, 2024

Oct 3, 2024, 10:00 AM EDT - 1 year ago

Climb Bio to Host Virtual Investor Event on October 15, 2024

Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.

Oct 2, 2024, 9:00 AM EDT - 1 year ago

Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.

Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit

Sep 11, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit

Eliem Therapeutics Announces Additions to its Leadership Team

Aug 26, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics Announces Additions to its Leadership Team

Eliem Therapeutics Reports Second Quarter Financial Results

Aug 14, 2024, 6:05 AM EDT - 1 year ago

Eliem Therapeutics Reports Second Quarter Financial Results

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Jun 28, 2024, 1:58 PM EDT - 1 year ago

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes

Jun 28, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes

Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement

Jun 27, 2024, 4:01 PM EDT - 1 year ago

Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement

Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

Eliem Therapeutics' stock soars 21% premarket after company says it may sell itself

Jul 20, 2023, 6:57 AM EDT - 2 years ago

Eliem Therapeutics' stock soars 21% premarket after company says it may sell itself

Eliem Therapeutics Announces Plans to Explore Strategic Alternatives

Jul 20, 2023, 6:45 AM EDT - 2 years ago

Eliem Therapeutics Announces Plans to Explore Strategic Alternatives

Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights

May 11, 2023, 4:10 PM EDT - 2 years ago

Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights

Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights

Mar 6, 2023, 4:10 PM EST - 2 years ago

Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights

Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition

Feb 9, 2023, 4:01 PM EST - 2 years ago

Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition

Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference

Nov 30, 2022, 7:00 AM EST - 3 years ago

Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference

Eliem Therapeutics Reports Third Quarter Financial and Business Highlights

Nov 14, 2022, 6:10 AM EST - 3 years ago

Eliem Therapeutics Reports Third Quarter Financial and Business Highlights

Eliem Therapeutics to Participate at Two Upcoming Investor Conferences

Nov 8, 2022, 7:00 AM EST - 3 years ago

Eliem Therapeutics to Participate at Two Upcoming Investor Conferences

Eliem Therapeutics Provides Update on Pipeline Progress

Oct 5, 2022, 7:00 AM EDT - 3 years ago

Eliem Therapeutics Provides Update on Pipeline Progress

Eliem Therapeutics Reports Second Quarter Financial and Business Highlights

Aug 15, 2022, 6:10 AM EDT - 3 years ago

Eliem Therapeutics Reports Second Quarter Financial and Business Highlights

Eliem's stock slides 20% after saying it will discontinue development of pain treatment

Aug 2, 2022, 9:33 AM EDT - 3 years ago

Eliem's stock slides 20% after saying it will discontinue development of pain treatment

Eliem Therapeutics Provides ETX-810 Program Update

Aug 2, 2022, 7:00 AM EDT - 3 years ago

Eliem Therapeutics Provides ETX-810 Program Update

Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder

Jul 18, 2022, 7:00 AM EDT - 3 years ago

Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder

Eliem Therapeutics to Host Virtual Investor Event on July 21, 2022

Jul 7, 2022, 7:00 AM EDT - 3 years ago

Eliem Therapeutics to Host Virtual Investor Event on July 21, 2022

Eliem Therapeutics Announces Last Patient Completed Dosing in Phase 2a Study of ETX-810 in Patients with Lumbosacral Radicular Pain (LSRP)

Jun 27, 2022, 4:01 PM EDT - 3 years ago

Eliem Therapeutics Announces Last Patient Completed Dosing in Phase 2a Study of ETX-810 in Patients with Lumbosacral Radicular Pain (LSRP)

5 Short Squeeze Candidates To Watch This Week: Revlon Tops The List, A SPAC Shifts To Second And More

Jun 21, 2022, 12:01 PM EDT - 3 years ago

5 Short Squeeze Candidates To Watch This Week: Revlon Tops The List, A SPAC Shifts To Second And More

TXMD WEBR

5 Short Squeeze Candidates To Watch This Week: TherapeuticsMD Tops List While This Arts And Crafts Retailer Joins The Leaderboard

Jun 13, 2022, 10:49 AM EDT - 3 years ago

5 Short Squeeze Candidates To Watch This Week: TherapeuticsMD Tops List While This Arts And Crafts Retailer Joins The Leaderboard

TXMD BEEM

5 Short Squeeze Candidates To Watch This Week: Vertex Energy Tops List, Medavail Holdings And Camping World Remain Elevated

May 16, 2022, 11:38 AM EDT - 3 years ago

5 Short Squeeze Candidates To Watch This Week: Vertex Energy Tops List, Medavail Holdings And Camping World Remain Elevated

CWH VERU

Eliem Therapeutics Reports First Quarter Financial and Business Highlights

May 16, 2022, 6:10 AM EDT - 3 years ago

Eliem Therapeutics Reports First Quarter Financial and Business Highlights

cheating_stock_investor
cheating_stock_investor Sep. 3 at 4:50 PM
$CLYM when this board gets more activity some will say how was I here at the bottom again
0 · Reply
Ralphbeach
Ralphbeach Aug. 27 at 7:41 PM
$IXHL so many other stocks to invest in. This Australia dog has too many fleas. Too many hurdles...all the phases. All the cash needed. The pumpers on all the different social media. Too much competition with companies that have a stronger balance sheet. Look at $ACHV $CUE $LCTX $CLYM
3 · Reply
cheating_stock_investor
cheating_stock_investor Aug. 25 at 2:28 PM
$CLYM cash plus value of assets 3+2 minimum =5 Steal here.
0 · Reply
StockScanners
StockScanners Aug. 23 at 7:08 PM
$CLYM reached 2.42
2 · Reply
BigWins3
BigWins3 Aug. 23 at 11:17 AM
$CLYM This is my Grandpa Palphie, he pays for a stocktwits monthly membership and pretends he has lots of money, rest assured grandma left him because he was caught wearing her under garmets and playing dress up. I hate to air out our family's dirty laundry but he was wearing it so I have no choice.
1 · Reply
SpectreStrat
SpectreStrat Aug. 23 at 9:24 AM
$CLYM The Calamos Dynamic Convertible and Income Fund is a leveraged closed-end convertible fund
0 · Reply
Ralphbeach
Ralphbeach Aug. 23 at 1:18 AM
BIGwins...$CLYM take your lunch money and buy some. With your gains enroll in charm school. Peace ✌️ out
1 · Reply
cheating_stock_investor
cheating_stock_investor Aug. 22 at 2:14 PM
$CLYM very quiet board yet slow accumulation increase in stock price. Tells you this is the place to be with no noise
0 · Reply
StockScanners
StockScanners Aug. 21 at 12:32 AM
$CLYM keep watch if this holds above 2.10
0 · Reply
Chumpchange53
Chumpchange53 Aug. 20 at 9:30 PM
$CLYM Wash ,rinse, repeat kind of day
0 · Reply
cheating_stock_investor
cheating_stock_investor Aug. 20 at 7:01 PM
$CLYM is kt still active?
0 · Reply
macd87
macd87 Aug. 20 at 2:07 PM
$CLYM what is going on, how come no volume in the middle of the week
0 · Reply
Chumpchange53
Chumpchange53 Aug. 18 at 8:35 PM
$CLYM BOOOOYAAAAAAA!!!!
0 · Reply
Nfjkdjndnd
Nfjkdjndnd Aug. 18 at 4:20 PM
$CLYM if this stays sideways around $2, I’ll be watching for a straight line up to $2.20+ at some point today
0 · Reply
vu_jade
vu_jade Aug. 18 at 2:36 PM
$CLYM as in Climb!
0 · Reply
cheating_stock_investor
cheating_stock_investor Aug. 18 at 2:23 PM
$CLYM creeping up sleeper stock ready to trade above cash value with a little good news. Friend of mine gave this to me not too long ago with 6 dollar pt.
0 · Reply
kaefer
kaefer Aug. 16 at 8:21 AM
$CLYM Nice setup!
0 · Reply
vu_jade
vu_jade Aug. 15 at 4:57 PM
$CLYM climbing
0 · Reply
kshonstocks
kshonstocks Aug. 15 at 3:32 PM
$CLYM Climb Bio initiated with an Outperform at Baird on budoprutug potential 09:06 CLYM As previously reported, Baird initiated coverage of Climb Bio with an Outperform rating and $9 price target per the fly
0 · Reply
kshonstocks
kshonstocks Aug. 15 at 3:24 PM
$CLYM is 200 dma b/o
0 · Reply
JarvisFlow
JarvisFlow Aug. 15 at 2:19 PM
Baird has adjusted their stance on Climb Bio ( $CLYM ), setting the rating to Outperform with a target price of 9.
0 · Reply
Fakhrul123
Fakhrul123 Aug. 14 at 8:12 PM
$CLYM According to Wall Street analysts, ClimbBio (CLYM) stock is expected to rise over the next 12 months. The average 1-year price target is around $9.00 to $10.20, with a high of $10.50 and a low of $7.00. Analysts have given the stock a consensus rating of "Buy".
0 · Reply